The utility of F-FDG PET/CT in assessing bone marrow involvement and prognosis in newly diagnosed diffuse large B-cell lymphoma.
[BACKGROUND] The presence of bone marrow involvement (BMI) in patients with diffuse large B-cell lymphoma (DLBCL) has a significant impact on treatment plans and prognosis, but clinical diagnosis is d
- p-value p = 0.010
- Sensitivity 94.1%
APA
Yang C, Liu H, et al. (2025). The utility of F-FDG PET/CT in assessing bone marrow involvement and prognosis in newly diagnosed diffuse large B-cell lymphoma.. Radiology and oncology, 59(4), 488-497. https://doi.org/10.2478/raon-2025-0062
MLA
Yang C, et al.. "The utility of F-FDG PET/CT in assessing bone marrow involvement and prognosis in newly diagnosed diffuse large B-cell lymphoma.." Radiology and oncology, vol. 59, no. 4, 2025, pp. 488-497.
PMID
41401061
Abstract
[BACKGROUND] The presence of bone marrow involvement (BMI) in patients with diffuse large B-cell lymphoma (DLBCL) has a significant impact on treatment plans and prognosis, but clinical diagnosis is difficult. The purpose of this study was to evaluate the utility of PET/CT in the assessment of BMI and prognosis in newly diagnosed DLBCL.
[PATIENTS AND METHODS] This retrospective study included 57 eligible DLBCL patients who underwent bone marrow biopsy (BMB) and PET/CT prior to any treatment initiation. Increased FDG uptake in the bone marrow on PET/CT scans was indicative of BMI positivity, with such instances not attributable to benign findings. If BMB yielded positive results, or if the marrow uptake resolved concurrently with other lymphoma lesions during PET/CT monitoring, the diagnosis of BMI was established. The evaluation of bone marrow status via PET/CT involved both visual analysis and a quantitative index, specifically the ratio of maximum standardized uptake values of bone marrow to liver (BLR). Factors associated with 2-year progression-free survival (PFS) was analyzed utilizing the Cox proportional hazards regression model.
[RESULTS] 34 patients were diagnosed with BMI. PET/CT demonstrated superior accuracy (93.0% . 75.4%) and sensitivity (94.1% . 58.8%) compared to BMB. During the follow-up period, 15 patients experienced disease progression. Survival analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS), BLR, and PET/CT bone marrow status as the sole independent predictors of PFS (p = 0.010, 0.002, and 0.015, respectively).
[CONCLUSIONS] PET/CT played an important role in evaluating BMI and predicting PFS in newly diagnosed DLBCL.
[PATIENTS AND METHODS] This retrospective study included 57 eligible DLBCL patients who underwent bone marrow biopsy (BMB) and PET/CT prior to any treatment initiation. Increased FDG uptake in the bone marrow on PET/CT scans was indicative of BMI positivity, with such instances not attributable to benign findings. If BMB yielded positive results, or if the marrow uptake resolved concurrently with other lymphoma lesions during PET/CT monitoring, the diagnosis of BMI was established. The evaluation of bone marrow status via PET/CT involved both visual analysis and a quantitative index, specifically the ratio of maximum standardized uptake values of bone marrow to liver (BLR). Factors associated with 2-year progression-free survival (PFS) was analyzed utilizing the Cox proportional hazards regression model.
[RESULTS] 34 patients were diagnosed with BMI. PET/CT demonstrated superior accuracy (93.0% . 75.4%) and sensitivity (94.1% . 58.8%) compared to BMB. During the follow-up period, 15 patients experienced disease progression. Survival analysis identified Eastern Cooperative Oncology Group performance status (ECOG PS), BLR, and PET/CT bone marrow status as the sole independent predictors of PFS (p = 0.010, 0.002, and 0.015, respectively).
[CONCLUSIONS] PET/CT played an important role in evaluating BMI and predicting PFS in newly diagnosed DLBCL.
MeSH Terms
Humans; Lymphoma, Large B-Cell, Diffuse; Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18; Female; Male; Middle Aged; Retrospective Studies; Prognosis; Aged; Bone Marrow; Radiopharmaceuticals; Adult; Aged, 80 and over; Progression-Free Survival
같은 제1저자의 인용 많은 논문 (5)
- Estimating major pathological response in non-small cell lung cancer patients with post-neoadjuvant therapy using MMT-net.
- Long-term fine particulate air pollution exposure and risk of gastric cancer mortality in Taiwan.
- A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity.
- Lactylation as a metabolic-epigenetic switch in cancer: dual roles in cell death resistance and therapeutic vulnerability.
- Development of a machine learning model for preoperative prediction of spread through air spaces in resectable non-small cell lung cancer: A single-center retrospective study.